Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express, Inc. reports developments tied to its PetMeds pet pharmacy platform, its PetCareRx business, and the sale of prescription and non-prescription pet medications, preventatives, health products, and supplies. The company serves pet owners through direct-to-consumer channels and has announced distribution partnerships that extend pet pharmacy offerings across retail and digital channels.
Recurring news themes include product assortments focused on pet wellness, fiscal results and financial reporting updates, Nasdaq listing-rule communications related to periodic filings, board and audit committee changes, shareholder rights plan actions, and responses to unsolicited acquisition proposals. Coverage also reflects the company's positioning as a national pet pharmacy and pet health products retailer.
PetMeds (Nasdaq: PETS) announced a strategic partnership with Rural King on April 22, 2026 to launch a white-label pet pharmacy across Rural King retail stores and digital channels.
PetMeds will supply pharmacy infrastructure, licensed pharmacists and e-commerce capabilities to expand access to prescription medications, preventatives and pet health products, targeting millions of Rural King customers in rural communities.
Cardone Ventures submitted an unsolicited, non-binding all-cash proposal to acquire PetMed Express (Nasdaq: PETS) for $4.25 per share, implying an equity value of approximately $89 million on December 16, 2025.
The proposal is not subject to a financing contingency and is led by Brandon Dawson, Natalie Dawson, and Grant Cardone. Cardone Ventures highlights operational experience including scaling its firm to about $225 million in revenue in five years and managing over $2 billion in assets under management; Grant Cardone is described as managing over $5 billion of assets.
The offer is non-binding and conditioned on customary due diligence, a definitive agreement, and required approvals, and there is no assurance a transaction will be completed.
PetMeds (Nasdaq: PETS) confirmed receipt on Dec 11, 2025 of an unsolicited, non-binding proposal from SilverCape Investments Limited to acquire all outstanding shares for $4.00 per share in cash. The offer is subject to due diligence and execution of a definitive agreement but is not conditioned on financing. SilverCape publicly disclosed the proposal in an amendment to its Schedule 13D filed with the SEC on Dec 11, 2025. The PetMeds board, with financial and legal advisers, will review the proposal consistent with its fiduciary duties. The company said this letter is not a formal offer capable of acceptance and stockholders need take no action at this time.
PetMeds (Nasdaq: PETS) unveiled its 2025 Holiday Collection on December 10, 2025: a curated assortment of wellness-focused gifts for pets and pet parents emphasizing health, safety, and everyday comfort.
The collection highlights grooming items, first-aid and screening tests (including an at-home cancer urine test and multiple DNA tests), toys, treats, cat monitoring devices, equine grooming and supplements, and natural pest-repellent collars. The Holiday Giftable Essentials Collection is available now at PetMeds.com with fast shipping and subscription options for select items.
PetMeds (Nasdaq: PETS) announced that its Board unanimously approved an amendment extending the company’s existing shareholder rights plan by one year, moving the expiration from December 2, 2025 to December 2, 2026. All other terms remain unchanged.
The Board said the extension is intended to protect shareholders while it believes the stock does not reflect the company’s inherent value and because of recent significant accumulations of company common stock by certain shareholders. The Rights Plan is intended to ensure fair treatment and to guard against acquisitions without payment of an appropriate control premium. A Form 8-K will provide further details.
PetMed Express (Nasdaq: PETS) announced preliminary fiscal Q2 2026 results and filed a Form 12b-25 notifying the SEC of a late 10-Q filing for the quarter ended September 30, 2025. The Company estimates Q2 net sales of $43.4M–$44.5M versus $58.0M in the prior year and six-month net sales of $94.5M–$95.6M versus $124.3M prior. The company reported $36.1M cash and no debt as of September 30, 2025.
The Company cannot yet estimate operating or net income while it analyzes the timing and amount of an anticipated goodwill impairment. Nasdaq sent a notice of non-compliance; the company must update its plan by November 28, 2025, and any Nasdaq exception may be limited to December 29, 2025. The notice does not have an immediate effect on the stock listing.
PetMed Express (Nasdaq: PETS) appointed James LaCamp to its Board effective immediately and named him Chair of the Audit Committee, effective October 30, 2025. Mr. LaCamp qualifies as an audit committee financial expert and brings nearly two decades of finance, accounting, and audit experience including 12+ years as an audit partner at Deloitte.
The Board now has six directors, five independent, and has added four directors since 2024 as part of ongoing board refreshment.
PetMeds (NASDAQ: PETS) filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
Key fiscal 2025 results: net sales $227.0 million (below prior preliminary range of $231.6–$233.6 million), net loss $6.3 million (wider than prior preliminary $4.5–$5.0 million), and cash $54.7 million with no debt. The company recorded a $1.2 million non-cash intangible impairment and restated promotional sales reimbursements from revenue to cost of sales, which the company says did not affect net income.
Management said it will file Form 10-Q for Q1 ended June 30, 2025 and subsequent quarterly filings "as soon as practicable" but gave no firm dates.
PetMed Express (NASDAQ: PETS) announced a September 9, 2025 award of 15,000 restricted common shares to Ali Khan upon his hiring as Chief Information Security Officer. The grant was made under the 2024 Inducement Incentive Plan and designated a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The shares vest in equal one-third increments on each of the first three anniversaries of the vesting commencement date, August 20, 2025, subject to continued employment.
PetMed Express (NASDAQ: PETS) announced significant leadership changes as CEO Sandra Campos and CFO Robyn D'Elia have resigned from their positions. Board Chair Leslie C.G. Campbell has been appointed as Interim CEO, while Chief Accounting Officer Douglas Krulik will serve as Interim Principal Financial Officer.
The departing executives will receive 13 months of base salary continuation and accelerated vesting of certain restricted stock units as severance, along with providing consulting services for three months. The company has initiated a search for permanent CEO and CFO positions. The Board has been restructured with Justin Mennen appointed as Lead Independent Director, while Peter Batushansky and Leah Solivan will chair the Audit and Compensation committees respectively.